Targeting the HIF2-VEGF axis in renal cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The von Hippel-Lindau (VHL) tumor suppressor protein plays a critical role in cellular oxygen sensing.
• VHL inactivation leads to the stabilization of hypoxia-inducible factors (HIFs), promoting tumor growth, particularly in clear-cell renal cell carcinoma (ccRCC).

Purpose of the Study:

• To review the mechanistic understanding of oxygen sensing and hypoxia signaling.
• To highlight the development of HIF2α-targeted therapies for VHL-associated tumors.
• To explore future applications of these therapies in other cancer types.

Main Methods:

• Review of existing literature on VHL, HIF, VEGF, and related signaling pathways.
• Analysis of clinical development of targeted therapies, including VEGF inhibitors and HIF2α inhibitors.
• Discussion of current treatment strategies and future directions.

Main Results:

• VEGF inhibitors are approved for ccRCC treatment.
• A HIF2α inhibitor is in phase 3 development for ccRCC.
• Combinations of targeted therapies with immune-checkpoint blockers are increasingly used.

Conclusions:

• Understanding oxygen sensing and hypoxia signaling has paved the way for HIF2α-targeted therapies in VHL-associated cancers.
• These targeted therapies, including VEGF inhibitors and HIF2α inhibitors, represent significant advancements in ccRCC treatment.
• Further research may extend the utility of these therapies to a broader range of cancers.